<DOC>
	<DOCNO>NCT00003076</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use drug try prevent development recurrence cancer . It know whether eflornithine effective preventing cancer patient Barrett 's esophagus . PURPOSE : Randomized double-blinded phase II trial study effectiveness eflornithine prevent cancer patient Barrett 's esophagus .</brief_summary>
	<brief_title>Eflornithine Prevent Cancer Patients With Barrett 's Esophagus</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether oral eflornithine ( DFMO ) give study cause significant reduction Ki67 label index subject intestinal type Barrett 's esophagus low grade dysplastic Barrett 's esophagus . II . Determine whether oral DFMO alter pathology morphology Barrett 's esophagus . III . Determine whether difference cellular DNA ploidy and/or nuclear nucleolar morphometry patient dysplastic Barrett 's esophagus nondysplastic intestinal type Barrett 's esophagus compare normal gastric fundic mucosa . Determine whether DFMO modulates change surrogate endpoint biomarkers towards normal mucosal value . IV . Determine whether cell demonstrate nuclear p53 protein accumulation either lose undergo change cellular distribution , follow treatment patient dysplastic Barrett 's mucosa DFMO . V. Determine whether DFMO modulates change growth factor oncogene expression dysplastic Barrett 's esophagus nondysplastic intestinal type Barrett 's esophagus . VI . Determine whether pathologic biologic surrogate modulation occur 6 month DFMO treatment revert 6 month treatment discontinue . OUTLINE : This randomize , placebo control , double blind prevention study . Patients initially stratify dysplasia status baseline ( metaplastic v low grade dysplastic ) treatment group ( placebo v eflornithine ) . Patients randomize receive daily dos eflornithine ( DFMO ) placebo 26 week . At 0 , 4 , 8 , 12 , 16 , 20 , 26 week toxicity adherence evaluation week 26 52 patient follow-up endoscopy . PROJECTED ACCRUAL : A total 152 evaluable patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must columnar line esophagus meet follow criterion : Specialized intestinal metaplasia Nondysplastic low grade dysplasia Extends minimum 1 cm gastroesophageal junction PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm3 Platelet count great 120,000/mm3 Hemoglobin great 12 g/dL Prothrombin time le 3 second beyond control Partial thromboplastin time le 10 second beyond control Hepatic : Bilirubin le 1.5 mg/dL Transaminases le 1.5 time normal Renal : Creatinine le 1.5 mg/dL Urinalysis : le 1+ protein , 03 urinary cast , 05 white blood cell red blood cell Cardiovascular : No severe dyspnea rest , orthopnea , edema , history congestive heart failure require continue treatment , unstable angina Neurologic : No severe degenerative neurologic disease Pulmonary : No requirement supplemental oxygen exertion rest Other : No prior malignancy within 5 year No active rheumatoid arthritis , lupus rheumatologic autoimmune disease ( less 2 year quiescence inactive ) No history abnormal wound heal No history esophageal varix variceal bleed Not pregnant nursing Negative pregnancy test Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : No regular , schedule use antiinflammatory medication , steroid , anticoagulants No nutritional supplement two multivitamin per day four single nutrient vitamin supplement per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>esophageal cancer</keyword>
</DOC>